文献速递衰弱、肌少症与跌倒老年慢病共病管理多重用药

衰弱与射血分数降低心衰患者ARNI使用情况

Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction.
PubMed 文献 · J Am Geriatr Soc · 2023-06-22

该研究利用2015-2019年Medicare数据,分析147,506-180,386名HFrEF患者中ARNI和GDMT的使用情况。结果显示ARNI使用率在衰弱与非衰弱患者中均上升,但衰弱患者使用全部3类GDMT的比例变化极小,且衰弱与年龄≥85岁、痴呆均与ARNI启动几率降低相关。

要点

  • 衰弱患者中ARNI使用率从0.3%升至13.7%,非衰弱患者从0.4%升至16.4%。
  • 衰弱患者使用全部3类GDMT的比例变化极小(19.6%-21.8%),非衰弱患者从22.0%升至27.0%。
  • 衰弱、痴呆、年龄≥85岁均与ARNI启动几率降低相关。

核心结论

  • 结果提示Medicare HFrEF受益人中ARNI和GDMT的使用存在证据-实践差距,尤其是衰弱患者。

研究设计与样本

  • 基于2015-2019年Medicare数据的分析,纳入147,506-180,386名HFrEF受益人(平均年龄77岁,27%女性,42.6%-49.1%衰弱)。
  • 衰弱状态由基于索赔的衰弱指数定义。
  • 使用逻辑回归识别与ARNI启动相关的临床特征,使用Cox比例风险回归分析2015年GDMT使用与2016-2019年死亡或心衰住院的关联。

主要发现

  • ARNI使用率在非衰弱患者中从0.4%升至16.4%,在衰弱患者中从0.3%升至13.7%(衰弱分层年趋势P=0.970)。
  • 在未使用肾素-血管紧张素系统阻滞剂的患者中,年龄≥85岁(OR 0.89,95%CI 0.80-0.99)、痴呆(OR 0.88,95%CI 0.81-0.96)和衰弱(OR 0.87,95%CI 0.81-0.94)与ARNI启动几率降低相关。
  • 使用全部3类GDMT的比例在非衰弱患者中从22.0%升至27.0%,在衰弱患者中变化极小(19.6%-21.8%)。
  • 无论衰弱状态如何,使用至少1类GDMT与较低的死亡或心衰住院风险相关(HR 0.94 [95%CI 0.91-0.97]、0.92 [0.89-0.94]、0.94 [0.91-0.97]分别对应1、2、3类)。

关键数值与推荐

  • ARNI使用率变化:非衰弱患者0.4%-16.4% vs 衰弱患者0.3%-13.7%(衰弱分层年趋势P=0.970)。
  • 全部3类GDMT使用率变化:非衰弱患者22.0%-27.0% vs 衰弱患者19.6%-21.8%。
  • ARNI启动的OR:年龄≥85岁0.89(95%CI 0.80-0.99),痴呆0.88(95%CI 0.81-0.96),衰弱0.87(95%CI 0.81-0.94)。
  • GDMT与死亡或心衰住院的HR:1类0.94(95%CI 0.91-0.97),2类0.92(95%CI 0.89-0.94),3类0.94(95%CI 0.91-0.97)。

临床怎么用

  • 在Medicare HFrEF受益人中,ARNI和GDMT的使用存在证据-实践差距,尤其是衰弱患者。
  • 需要努力缩小这一差距以减轻老年人的HFrEF负担。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frail older adults may be less likely to receive guideline-directed medical therapy (GDMT)-renin-angiotensin blockers, beta-blockers, and mineralocorticoid receptor antagonists-for heart failure with reduced ejection fraction (HFrEF). We aimed to examine the uptake of angiotensin receptor neprilysin inhibitor (ARNI) and GDMT in frail older adults with HFrEF. METHODS: Using 2015-2019 Medicare data, we estimated the proportion of beneficiaries with HFrEF receiving ARNI and GDMT each year by frailty status, defined by a claims-based frailty index. Logistic regression was used to identify clinical characteristics associated with ARNI initiation. Cox proportional hazards regression was used to examine the association of GDMT use in 2015 and death or heart failure hospitalization in 2016-2019. RESULTS: Among 147,506-180,386 beneficiaries with HFrEF (mean age: 77 years; 27% women; 42.6-49.1% frail) in 2015-2019, the proportion of patients receiving ARNI increased in both non-frail (0.4%-16.4%) and frail (0.3%-13.7%) patients (p for yearly-trend-by-frailty = 0.970). Among those not receiving a renin-angiotensin system blocker, patients with age ≥ 85 years (odds ratio [95% CI], 0.89 [0.80-0.99]), dementia (0.88 [0.81-0.96]), and frailty (0.87 [0.81-0.94]) were less likely to initiate ARNI. The proportion of patients receiving all 3 GDMT classes increased in non-frail patients (22.0%-27.0%) but changed minimally in frail patients (19.6%-21.8%). Regardless of frailty status, treatment with at least 1 class of GDMT was associated with lower death or heart failure hospitalization than no GDMT medications (hazard ratio [95% CI], 0.94 [0.91-0.97], 0.92 [0.89-0.94], 0.94 [0.91-0.97] for 1, 2, and 3 classes, respectively). CONCLUSIONS: Our results suggest an evidence-practice gap in the use of ARNI and GDMT in Medicare beneficiaries with HFrEF, particularly those with frailty. Efforts to narrow this gap are needed to reduce the burden of HFrEF in older adults.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Lee YC, Lin JK, Ko D, et al. Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction. J Am Geriatr Soc. 2023. PMID: 37345734. doi:10.1111/jgs.18481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。